Latest news with #crossCountry
RNZ News
06-07-2025
- Sport
- RNZ News
Equestrian: New Zealand wins Nations Cup
Tim Price rides Vitali during the cross-country at the Nations Cup event at CHIO Aachen in Germany. 5 July 2025. Photo: Libby Law The New Zealand equestrian team have won the Nations Cup for just the second time, with Tim Price the individual winner at CHIO Aachen in Germany. Four New Zealanders finished in the top 10, with Price leading through all phases for his victory on Vitali, clinching the individual and team gold medals with a brilliant cross-country round. The successful pair had 30.5 penalty points, giving Price his first individual victory at Aachen, one of the world's toughest equestrian events. Monica Spencer on Artist finished sixth with 37.2 penalty points, Clarke Johnstone on Rocket Man (40.8) ninth, and individual rider Jonelle Price on Hiarado (41.3) 10th. The other team member, Samantha Lissington, finished 22nd on Lord Seekonig. Great Britain looked the likely winners of the event, but the New Zealanders dug deep to triumph by 8.7 penalty points, with the United States second and the British team third. Tim Price and Johnstone were in the New Zealand team that won the Nations Cup in 2018, with Blyth Tait and Sir Mark Todd. Price finished third on individual points that year and has also had two fourths at Aachen. Spencer and Artist, who had travelled from their US base for the event, had the quickest cross-country round, going clear with just 0.4 time penalties. Spencer, Johnstone and the Prices all had clear showjumping rounds, adding just time penalties. Tim Price felt the showjumping, which had sometimes been a challenging phase for 15-year-old Vitali, had this time opened the door to victory for him. "He has always been a very good cross country horse and was super today. I am absolutely thrilled for the team.'' Equestrian Sports NZ general manager of high performance Jock Paget said he was thrilled with all five Kiwi combinations. Aachen had been a key target for the year and an important event given it will host the 2026 world championships. "To pull it off in this way is amazing," Paget said. "Aachen is a hard place to do well. "There was a huge amount of pressure with a very tough [cross country] course and the time wasn't achievable today but they all went out there and rode really competitively. They took a lot of risks, rode skilfully and got the job done. To have four New Zealanders in the top 10 at Aachen is amazing and to win double gold too. "Aachen to us is like our European championships - we don't have one but we treat it like that. It was the biggest target for us this year. There are Nations Cups and then there is Aachen. This was the pin in the map for us this year." Sign up for Ngā Pitopito Kōrero, a daily newsletter curated by our editors and delivered straight to your inbox every weekday.
Yahoo
25-06-2025
- Business
- Yahoo
TipRanks' ‘Perfect 10' Picks: 2 Top-Scoring Stocks That Are Ticking Every Box
Imagine planning a cross-country road trip with thousands of potential stops. You've got maps, reviews, GPS coordinates, weather forecasts – too much information, really. Some places look promising, others are hyped up but turn out to be duds. And without a smart guide, you're left second-guessing every turn. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter That's how investing can feel. Every stock is a destination, but figuring out which ones are worth the journey is overwhelming. Earnings, analyst opinions, insider trades – it's all useful, but hard to process when it comes at you from all directions. That's where TipRanks' Smart Score comes in. Think of it as your investment GPS. It's designed specifically to cut through the noise and highlight the most promising opportunities. Powered by AI, the system processes the massive flow of daily market data and distills it all into a single, simple number: a score from 1 to 10 that signals how likely a stock is to outperform in the months ahead. A 'Perfect 10' signals those stocks that deserve a closer look. So, let's go browsing through the top-scoring stocks on the TipRanks data platform. We can start with two that are ticking all the boxes, earning the 'Perfect 10' even in an uncertain market environment – and picking up investor attention for the right reasons. GDS Holdings (GDS) We'll start our look at 'Perfect 10' stocks with one of China's major data center holding firms, GDS Holdings. This company is an important player in China's growing technology industry, where it offers its customers a range of vital services. These include data center colocation, managed hosting, and managed cloud services. GDS's services are secure, reliable, and fault-tolerant—important attributes for a third-party provider. The company boasts that it brings value to the data center IT world, with data centers that feature plenty of net floor space, high power capacities, and multiple protective redundancies across mission-critical systems. The company is both carrier- and cloud-neutral, allowing its customers to access major telecom networks and public clouds. In its 24-year history of operations, GDS has built up a solid customer base, mainly composed of financial institutions, hyperscale cloud service providers, IT service providers, large internet firms, and telecom carriers. In addition, large domestic private sector and multinational corporations operating in China make use of GDS's services. This customer base is highly diverse, but GDS's customers are also known as highly demanding—meeting their needs is a sign of success for GDS. In addition to its operations in China, GDS owns a non-controlling stake of 35.6% in DayOne Data Centers Limited, which takes the development and operations of data centers and related services to the international markets. Turning to the company's financial results, we find that GDS realized $375.3 million in total revenues during 1Q25, in US currency. This figure was up 12% year-over-year, although it missed the forecast by $4.48 million. At the bottom line, GDS saw earnings of $0.48 per share in the quarter; in Chinese currency, this came to RMB3.47, and compared favorably to the net loss of RMB1.96 per share reported in 1Q24. Greg Miller, of Citizens JMP, covers this stock, and he is impressed by GDS's potential going forward. Pointing out the power capacity behind the company's data center operations, Miller goes on to outline the firm's attractive profile, writing, 'Following the near two-year slow down with companies taking more space, we now find the company poised to deliver as much as 900 MW of capacity over the next four years in China and yet another 700 MW of capacity outside of China in its international entity now called 'Day One.' We believe we are now back to a situation in which one should evaluate the total available capacity of its pipeline in order to assess its long-term value… With 900 MW domestic and 700 MW international to monetize, we believe consolidated revenues and EBITDA could double over the course of the next four years. With the C-REIT likely to be worth more than $30 per GDS share and the international company another $10, even before we fully assess the potential to sell through inventory, we continue to find the stock attractive for purchase.' In line with his description of the stock as 'attractive for purchase,' Miller rates the shares as Outperform (i.e., Buy), with a price target of $40 that implies an upside of 45% for the year ahead. (To watch Miller's track record, click here) GDS shares have a Strong Buy from the Street's analyst consensus, based on a unanimous 7 Buys. The shares are priced at $27.54, and their $37.19 average price target suggests that the stock will gain 35% on the one-year horizon. (See GDS stock forecast) BridgeBio Pharma (BBIO) Next on our list of 'Perfect 10s' is BridgeBio Pharma, a biomedical research company that is working on new treatments for rare and serious genetic diseases. The firm's targets are diseases with clear genetic drivers – conditions that are not just genetically linked, but are also known to be caused by single genetic mutations. The company points out that more than 10,000 such genetic disease conditions meet this description and affect tens of millions of patients around the world – but that there are fewer than 50 FDA-approved medications, making this a rich field for new biomedical research. BridgeBio has developed a proprietary drug development platform and takes a step-by-step approach to its research. The company first works to discover novel genetic disease targets and follows by creating medicines to alleviate symptoms and improve quality of life. The most important steps come next: bringing the drug candidates to the clinical trial and regulatory approval stages, and then moving on to commercialization. Currently, BridgeBio has seven trial programs in its drug development program. One of these, acoramidis, has reached the commercial stage, with approval from the FDA for the treatment of transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). Phase 3 studies of the drug showed rapid and durable, statistically significant improvements in patients under treatment, and the drug was approved by the FDA in November of last year. The company is currently marketing acoramidis under the name Attruby. The treatment of TTR-related conditions has become something of a hot topic recently in the biopharmaceutical field. The treatment of ATTR-CM alone is expected to have a potential market worth approximately $16 billion by 2030 (according to Grand View Research), and that has attracted both Pfizer and Alnylam as well. Alnylam's drug Amvuttra was approved in 2022 and brought in $970 million in sales last year. From the perspective of BridgeBio investors, this only highlights the potential in this field. We should note that, in 1Q25, BridgeBio reported its first full quarter after the approval of Attruby and revealed that it had $36.7 million in quarterly product revenue from the drug. BridgeBio's sound position in a potentially rich field has caught the attention of Andy Chen from Wolfe Research. Chen writes of the company, 'BBIO is in a favorable position narratively amid the 'TTR craze' (refer to strong performance of Alnylam). Regardless of market size (which we cannot substantiate) and clinical profile (we believe a few points in clinical efficacy are simply there to satisfy buyside trades and will not strongly sway therapy selection), we are believers in Bridge's execution strategy commercially, with strong tailwind due to the awkward design of the US healthcare system (though we do find it odd that Bridge is not exercising its prerogative to disadvantage Alnylam via steps – perhaps Bridge is quietly pushing this expense onto AstraZeneca/Ionis). Near-term stock upside is likely if Bridge posts linear or better revenue trajectory.' Chen follows these comments by rating the stock as Outperform (i.e., Buy), and he supports that with a price target of $49, showing his confidence in a 16% one-year upside. (To watch Chen's track record, click here) It's clear that Wall Street likes this stock, as BridgeBio has a Strong Buy consensus rating based on 16 recent recommendations that include 15 Buys and 1 Hold. The stock is selling for $42.18, and the average target price is more optimistic than Chen will permit; at $60.27, the figure points toward a gain of 43% in the year ahead. (See BBIO stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights. Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment. Disclaimer & DisclosureReport an Issue Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
31-05-2025
- Automotive
- Yahoo
4 Best Cars To Rent in 2025
Renting a car is sometimes a necessity. Other times, it's for convenience or fun. Whether you're planning a cross-country road trip, flying in for business or just need a dependable ride for the weekend that won't break the budget, the right rental makes all the difference. Read Next: Find Out: These car rental picks for 2025 offer comfort, value and performance. Weekend price: $200-$300 before taxes Whether it's a weekend road trip or an overnight camping trip with a pet, the Subaru Crosstrek is a great choice. The higher 9.3-inch ground clearance for the Crosstrek makes it perfect for driving in wooded areas. The Crosstrek also has a hatchback that allows for easy access to luggage, including a large pet carrier. Find Out: Weekend price: $400-$600 before taxes Splurge a little for that weekend class reunion by renting a BMW 5-Series, and impress classmates with the deluxe interior of the Luxury Seating package with heated and ventilated front seats that also have a massage feature. This BMW offers fuel economy of 27 mpg city and 35 mpg highway. Weekend price: $175-$250 before taxes Plan a romantic weekend getaway and rent a Toyota Corolla that has plenty of legroom and storage space for a couple. The Corolla is one of the most popular cars in the country, with excellent fuel economy up to 41 mpg on the highway. Weekend price: $250-$400 before taxes Rent a Jeep Compass and have an enjoyable time driving cross-country to visit family. The advanced, fuel-efficient powertrain options and 4×4 capability will make this a ride to remember. The Compass is rated at 32 mpg on the highway. Editor's note: Rental pricing was sourced from Turo and reflects estimated ranges for a Friday pick-up through Monday drop-off rental. Pricing and availability may vary depending on location. More From GOBankingRates Are You Rich or Middle Class? 8 Ways To Tell That Go Beyond Your Paycheck 6 Hybrid Vehicles To Stay Away From in Retirement This article originally appeared on 4 Best Cars To Rent in 2025
The Independent
07-05-2025
- Business
- The Independent
'Hands tied': Athletes left in dark as NCAA settlement leaves murky future for non-revenue sports
The $2.8 billion NCAA settlement awaiting final approval from a federal judge is touted as a solution for thousands of athletes to finally get the money they deserve and provide some clarity to recruiting. For some, it's too late. Sophomore distance runner Jake Rimmel says he was one of five walk-ons cut from Virginia Tech's cross country team after Thanksgiving break. Rimmel decided to take a leave of absence and train independently while considering his next move – something that's proven easier said than done. 'Everyone's got their hands tied right now, so there's just not many opportunities for me,' Rimmel told the Associated Press. 'I've just been having to bet on myself and trust the process. It's just been lonely. I've been at home training by myself and living with my family again. Thank God for my family and all, I appreciate them. It's still kind of lonely though, being out of the norm, not being at school and with my friends." Pending approval, the so-called House settlement will allow schools to share revenue with athletes directly for use of their name, image and likeness (NIL). That could secure generational wealth for some but not others, and replacing scholarship caps with roster limitations is expected to leave walk-ons, partial scholarship earners, non-revenue sport athletes and high school recruits at risk. There are deep concerns about the potential impact on sports that feed the U.S. Olympic teams. U.S. District Judge Claudia Wilken told attorneys handling the settlement to come back to her with a plan soon to protect athletes currently or recently on rosters at schools across the country, a request seen as a way to soften the blow. What that looks like is anyone's guess for now, but thousands of athletes like Rimmel have no idea where they might be this fall or are in jeopardy of no longer playing college sports at all. And many athletes balancing school and their sport are unaware of what's at stake and have more questions than answers. Belmont track and field athlete Sabrina Ootsburg said everything she knows about the settlement is from personal research. 'My school doesn't do a lot of education around it (the settlement). Every now and then, we'll be told, 'Hey, if you want to sign up to potentially get some money from this House settlement that's happening, you can do that,'' Ootsburg said. 'It's almost like the education we're being given is optional to consume, even though it's limited.' Oostburg is used to taking matters into her own hands, securing over 50 NIL deals by herself. She has contacted lawyers and asked for updates on the settlement, but she's not quite reassured. The chaotic nature of college athletics so obvious to the public is even worse for the athletes themselves. 'Being a college athlete, it's so hard to stay up to date with what's happening every day because it's so constantly changing,' she said. Smaller, non-revenue-generating programs don't often have a point person to navigate NIL deals or educate athletes. At Belmont, Ootsburg said, NIL-related responsibilities are managed by an already busy compliance office. 'To take time to learn about what's happening is just so time-consuming, especially if you're not in that one percent or one of the football players where they have people dedicated to helping them stay up to date,' she said. For now, thousands of athletes are trying to wrap up their spring semesters and many of them have league tournaments or even NCAA championship competition ahead before what many expect will be the final summer before college sports sees some of the most dramatic changes in history. For athletes like Rimmel, those changes are already here. Some of the others cut from the Virginia Tech program have given up on their dreams of collegiate running altogether. Rimmel hasn't given up completely; he spoke with his former coach recently, who said the Hokies' athletics department is still trying to figure out what's to come. 'I'm still kind of hoping I might be able to find my way back there next fall," he said. ___
Associated Press
07-05-2025
- Business
- Associated Press
‘Hands tied': Athletes left in dark as NCAA settlement leaves murky future for non-revenue sports
The $2.8 billion NCAA settlement awaiting final approval from a federal judge is touted as a solution for thousands of athletes to finally get the money they deserve and provide some clarity to recruiting. For some, it's too late. Sophomore distance runner Jake Rimmel says he was one of five walk-ons cut from Virginia Tech's cross country team after Thanksgiving break. Rimmel decided to take a leave of absence and train independently while considering his next move – something that's proven easier said than done. 'Everyone's got their hands tied right now, so there's just not many opportunities for me,' Rimmel told the Associated Press. 'I've just been having to bet on myself and trust the process. It's just been lonely. I've been at home training by myself and living with my family again. Thank God for my family and all, I appreciate them. It's still kind of lonely though, being out of the norm, not being at school and with my friends.' Pending approval, the so-called House settlement will allow schools to share revenue with athletes directly for use of their name, image and likeness (NIL). That could secure generational wealth for some but not others, and replacing scholarship caps with roster limitations is expected to leave walk-ons, partial scholarship earners, non-revenue sport athletes and high school recruits at risk. There are deep concerns about the potential impact on sports that feed the U.S. Olympic teams. U.S. District Judge Claudia Wilken told attorneys handling the settlement to come back to her with a plan soon to protect athletes currently or recently on rosters at schools across the country, a request seen as a way to soften the blow. What that looks like is anyone's guess for now, but thousands of athletes like Rimmel have no idea where they might be this fall or are in jeopardy of no longer playing college sports at all. And many athletes balancing school and their sport are unaware of what's at stake and have more questions than answers. Belmont track and field athlete Sabrina Ootsburg said everything she knows about the settlement is from personal research. 'My school doesn't do a lot of education around it (the settlement). Every now and then, we'll be told, 'Hey, if you want to sign up to potentially get some money from this House settlement that's happening, you can do that,'' Ootsburg said. 'It's almost like the education we're being given is optional to consume, even though it's limited.' Oostburg is used to taking matters into her own hands, securing over 50 NIL deals by herself. She has contacted lawyers and asked for updates on the settlement, but she's not quite reassured. The chaotic nature of college athletics so obvious to the public is even worse for the athletes themselves. 'Being a college athlete, it's so hard to stay up to date with what's happening every day because it's so constantly changing,' she said. Smaller, non-revenue-generating programs don't often have a point person to navigate NIL deals or educate athletes. At Belmont, Ootsburg said, NIL-related responsibilities are managed by an already busy compliance office. 'To take time to learn about what's happening is just so time-consuming, especially if you're not in that one percent or one of the football players where they have people dedicated to helping them stay up to date,' she said. For now, thousands of athletes are trying to wrap up their spring semesters and many of them have league tournaments or even NCAA championship competition ahead before what many expect will be the final summer before college sports sees some of the most dramatic changes in history. For athletes like Rimmel, those changes are already here. Some of the others cut from the Virginia Tech program have given up on their dreams of collegiate running altogether. Rimmel hasn't given up completely; he spoke with his former coach recently, who said the Hokies' athletics department is still trying to figure out what's to come. 'I'm still kind of hoping I might be able to find my way back there next fall,' he said. ___ AP college sports:
